JointHealth™ express   February 28, 2011

New addition to BC's drug formulary

BC PharmaCare has just added certolizumab pegol (Cimzia®), for use in the treatment of moderately to severely active rheumatoid arthritis (RA), to the formulary under the Special Authority program.

This is good news for British Columbians living with rheumatoid arthritis. Since every patient responds differently to disease suppressing or disease modifying medications, the more treatment options there are, the better.

Certolizumab pegol (Cimzia®) is an anti-TNF medication taken by one subcutaneous injection every two weeks (200mg/mL pre-filled syringe) used to treat RA.

To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manage your disease.

Click here to view the Special Authority Request forms, which provide the criteria for arthritis medications including certolizumab pegol. Please have a look at Arthritis Consumer Experts' updated Report Card on provincial formulary reimbursement listings for biologic response modifiers.